| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
AUSTIN, Texas—Privately held GenturaDx of Hayward,Calif., seeks to make nucleic acid testing more affordable and practical forlaboratories, while Luminex Corp. wants to expand its presence in the diagnosticand testing markets. This all comes together this month in the form of acash deal worth $50 million, under which Luminex has agreed to acquire GenturaDx.
 
 
GenturaDx is developing a polymerase chainreaction (PCR) system to enable rapid and accurate diagnosis with minimalsample volume, a technology for which Luminex expects to see commercialavailability of assays by early 2014—the company also aims to integrate the PCRsystem with its MultiCode-RTx chemistry to increase its status and share in themolecular diagnostic testing market.
 
 
"This acquisition accelerates the developmentof integrated sample processing capabilities for our technology, and alignswith our mission to reduce healthcare costs and improve clinical outcomes byproviding innovative and affordable solutions to today's clinicallaboratories," said Luminex CEO Patrick J. Balthrop. "The acquisition ofGenturaDX builds on our strategic investments to date and positions the companyto deliver ongoing growth by increasing our product portfolio, expanding ourmarket opportunities and leveraging our leadership position."

Luminex expects the acquisition will add about $6million in operating expenses this year, excluding acquisition-relatedexpenses. Additional payments beyond the $50 million up front may be made aswell, if GenturaDx meets future milestones or achieves product revenue targets.
 
 
 
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue